Olaparib as the first-line maintenance therapy in advanced-stage epithelial ovarian cancer patients with BRCA mutations - Real-world experience from Taiwan.

doi:10.1016/j.tjog.2025.01.016

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Olaparib as the first-line maintenance therapy in advanced-stage epithelial ovarian cancer patients with BRCA mutations - Real-world experience from Taiwan.

Taiwanese journal of obstetrics & gynecology - 1 Sept 2026

Tang Wei-Jiun, Chang Shu-Han, Chang Chen-Bin, Chen Wei-Chun, Wang You-Chen, Chen Min-Yu, Chou Hung-Hsueh

Abstract excerpt

OBJECTIVE: Advanced epithelial ovarian cancer frequently recurs despite good response to first-line treatment, making maintenance therapy essential. Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, demonstrated significant benefit in BRCA-mutated disease in the SOLO-1 trial; however, real-world data from Taiwan remain limited. MATERIALS AND METHODS: We conducted a retrospective cohort study of patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA2 Protein
Share to Carcinoma, Ovarian Epithelial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA1

Share to Maintenance Chemotherapy

Share to Phthalazines

Share to Piperazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Progression-Free Survival

Source

Open in PubMed

Identifiers

PMID: 42642151
DOI: 10.1016/j.tjog.2025.01.016

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.